ArticleRetinal cases & brief reports2025
PHOTOBIOMODULATION THERAPY FOR SEROUS PIGMENT EPITHELIUM DETACHMENT IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Article in Retinal cases & brief reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecular Mechanisms of Photobiomodulation in Retinal Diseases: Cytochrome c Oxidase, Mitochondrial Bioenergetics and Cytoprotective Signalling.International journal of molecular sciences · 2026Review
- Photobiomodulation Therapy with Low-Level Light in Chronic Central Serous Chorioretinopathy: A Pilot Study.Ophthalmology and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo report a case of giant pigment epithelium detachment (PED) secondary to chronic central serous chorioretinopathy successfully treated with photobiomodulation.
methodsThis is a case report.
resultsA 55-year-old man complained worsening of vision in the left eye over the last 18 months. A complete ophthalmological evaluation encompassing best-corrected visual acuity measurement, spectral-domain optical coherence tomography, fundus autofluorescence, fluorescein angiography, and microperimetry was performed. Spectral-domain optical coherence tomography showed several small PEDs around the macula in the right eye and a giant macular serous PED with subretinal fluid in the left eye. Fluorescein angiography disclosed multiple hyperfluorescent roundish areas in the posterior pole bilaterally, with a macular pooling in the left eye. A diagnosis of chronic central serous chorioretinopathy was made, and the patient underwent photobiomodulation with one session for a week for 4 weeks, followed by one session bi-weekly for 2 months. Spectral-domain optical coherence tomography of the left eye showed a gradual flattening of the macular PED at 3 months, with a complete regression of the latter and of the subretinal fluid at 6-month and 12-month follow-up with no residual signs of chorioretinal atrophy on fundus autofluorescence. Best-corrected visual acuity improved from 20/80 at baseline to 20/25 at the last follow-up, and this functional improvement was further confirmed by microperimetry.
conclusionPhotobiomodulation can be considered a safe and effective treatment strategy for the management of chronic central serous chorioretinopathy with subretinal fluid and serous PED.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.